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Abstract
Background: Poor targeting of antimicrobial drugs contributes to the millions of deaths each year from malaria,
pneumonia, and other tropical infectious diseases. While malaria rapid diagnostic tests have improved use of
antimalarial drugs, there are no similar tests to guide the use of antibiotics in undifferentiated fevers. In this study
we estimate the diagnostic accuracy of two well established biomarkers of bacterial infection, procalcitonin and C-
reactive protein (CRP) in discriminating between common viral and bacterial infections in malaria endemic settings
of Southeast Asia.
Methods: Serum procalcitonin and CRP levels were measured in stored serum samples from febrile patients
enrolled in three prospective studies conducted in Cambodia, Laos and, Thailand. Of the 1372 patients with a
microbiologically confirmed diagnosis, 1105 had a single viral, bacterial or malarial infection. Procalcitonin and CRP
levels were compared amongst these aetiological groups and their sensitivity and specificity in distinguishing
bacterial infections and bacteraemias from viral infections were estimated using standard thresholds.
Results: Serum concentrations of both biomarkers were significantly higher in bacterial infections and malaria than in
viral infections. The AUROC for CRP in discriminating between bacterial and viral infections was 0.83 (0.81–0.86) compared
with 0.74 (0.71–0.77) for procalcitonin (p < 0.0001). This relative advantage was evident in all sites and when stratifying
patients by age and admission status. For CRP at a threshold of 10 mg/L, the sensitivity of detecting bacterial infections
was 95 % with a specificity of 49 %. At a threshold of 20 mg/L sensitivity was 86 % with a specificity of 67 %. For
procalcitonin at a low threshold of 0.1 ng/mL the sensitivity was 90 % with a specificity of 39 %. At a higher threshold of
0.5 ng/ul sensitivity was 60 % with a specificity of 76 %.
Conclusion: In samples from febrile patients with mono-infections from rural settings in Southeast Asia, CRP was a highly
sensitive and moderately specific biomarker for discriminating between viral and bacterial infections. Use of a CRP rapid
test in peripheral health settings could potentially be a simple and affordable measure to better identify patients in need
of antibacterial treatment and part of a global strategy to combat the emergence of antibiotic resistance.
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Background
Millions of deaths in the tropics each year follow a bac-
terial, viral, or malarial infection that often initially
present as undifferentiated fever [1]. Many febrile pa-
tients seek care at peripheral levels of the healthcare sys-
tem where diagnostic capacities are minimal. Given that
malaria and bacterial infections may be rapidly fatal,
overtreatment with antimicrobials is common, contrib-
uting to drug resistance that threatens global public
health [2–4].
Widespread deployment of malaria rapid tests revolu-
tionized the management of fever, until then treated pre-
sumptively with antimalarials [5]. It also revealed the
role of many non-malarial infections as common causes
of illness, highlighting the challenges in their diagnosis
and treatment. In many endemic areas where malaria
transmission is usually low and seasonal such as
Southeast Asia, the majority of fevers will have a nega-
tive malaria test. While health workers can refrain safely
from providing antimalarials to these patients, they have
limited capacity to diagnose and treat other causes of ill-
ness. This compromises immediate health outcomes as
well as patients’ confidence and future utilisation of
public health services.
There are numerous challenges to diagnosis and treat-
ment of infectious diseases in these settings. First, the
limited epidemiological evidence available indicates high
spatial and temporal heterogeneity in incidence of infec-
tions such as leptospirosis, dengue and rickettsioses [6].
Second, community and low level health facility workers
often have minimal training and have only recently
emerged from a mind-set that all fevers should be
treated presumptively with antimalarials [7]. Third, and
perhaps most important, there are few point of care
tests, other than malaria rapid diagnostic tests (RDTs),
which are sufficiently accurate and appropriate for these
settings. Syndromic based treatment algorithms such as
the Integrated Management of Childhood Illness (IMCI)
provide simple guidelines to improve the targeting of an-
tibiotics and referral decisions; however evaluations of
IMCI have shown mixed results in achieving this [8].
An alternative approach is to use biomarkers of inflam-
mation to identify patients likely to benefit from antibi-
otics or referral to higher level facilities. Procalcitonin and
C-reactive protein (CRP) are established biomarkers of
bacterial infections, and are widely used in high income
countries, particularly in hospital settings [9, 10]. In some
countries point-of-care CRP tests are also routinely used
in the community in patients with respiratory symptoms
and have reduced the use of antibiotics safely and cost-
effectively [11–13]. Extending this strategy to the tropics
could reduce unnecessary use of antibiotics and curtail
the spread of drug resistance. In low income countries this
is particularly important as second line antimicrobials can
be inaccessible. It remains critical, however, that patients
with infections who could benefit from an antibiotic are
identified correctly.
Thus far, there have been few comparative assessments
of procalcitonin and CRP in malaria endemic areas, and
those available have focused on hospitalised patients
[14–16]. In this study we carry out a preliminary explor-
ation of the role these biomarkers might have in periph-
eral settings in Southeast Asia to inform the use of
antibiotics in non-malarial fevers by estimating their
diagnostic accuracy in samples with well-defined viral
and bacterial infections.
Methods
Based on evidence from other settings [10, 17–22], we
hypothesised that procalcitonin and CRP serum levels
would be significantly higher in bacterial infections than
in viral infections in malaria endemic areas of Southeast
Asia. We tested this hypothesis using samples from pa-
tients with acute undifferentiated fever among whom an
infection was identified as the likely cause of illness.
Samples used in the study
We used stored serum samples from three aetiology of
fever studies carried out in the Angkor Hospital for
Children in Cambodia [23], in two provincial hospitals
in rural Laos [24], and in rural clinics on the Thai-
Myanmar border (manuscript in preparation; details
summarised in Table 1). In all three studies the samples
used for both microbiological investigations and for sub-
sequent procalcitonin and CRP measurement were ob-
tained on initial presentation, with convalescence
samples used to confirm diagnoses. Procalcitonin and
CRP were not routinely used for diagnosis and treatment
in these sites or to inform study recruitment. In the
Cambodian study a microbiological cause was identified
in almost 50 % of paediatric inpatients, in Laos 41 % of a
mixed inpatient and outpatient population (5 to 49 years
of age) were assigned a ‘conservative’ diagnosis (using
only culture, antigen detection, PCR, and for JEV IgM
ELISA), as were 51 % of clinic attendees in the Thai-
Myanmar border (children ≥5 years and adults of all
ages). Test strategies for each of the studies are sum-
marised in the supplementary file. Cases with a single
microbiological diagnosis were assigned to one of four
general aetiological groups: − viral infections, rickettsia,
and leptospira infections, bacteraemias, and malaria.
Our main interest was in the ability of the biomarkers to
distinguish between infections in the viral aetiological
group from those in either of the two bacterial
aetiological groups, as well as from the bacteraemia
group in isolation. We used 100 samples from healthy
blood donors from a blood bank in Bangkok, Thailand
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Table 1 Study sites and participants from whom stored samples were obtained
Cambodia Laos Thai/Myanmar border
Recruitment sites Paediatric hospital Two provincial hospitals in northwest and
southern Laos
Migrant and refugee clinics on the Thai/Myanmar border
Enrolment dates October 2009 to October 2010 May 2008 to December 2010; September
2008 to December 2010
March 2011 to March 2013
Patients recruited n = 1180 n = 1938 n = 1029
Patient demographics <16 years (69 % < 5); 45 % female; All inpatients 5–49 years (37 % < 15); 42 % female; 44 %
inpatients
≥5 years (45 % < 15 years); 36 % female; clinic attendants
Symptoms/syndromes used for
inclusion/exclusion
Documented axillary temperature ≥38 °C within
48 h of admission. All febrile inpatients were eligible
irrespective of symptoms/syndromes but excluding
post-surgical cases
Fever (tympanic ≥38 °C) with no obvious
cause < 8 days and eligible for a malaria
test by Laos national guidelines (patients
with obvious causes of fever such as abscess
or severe diarrhoea were excluded)
Documented fever ≥38 °C of up to seven days duration
with no obvious cause. Patients with a clear
clinical diagnosis such as chickenpox, pneumonia
(based on clinical criteria), skin/soft tissue infection
(e.g. cellulitis), or urinary tract infection were excluded
Documented mortality 5.6 % 0.5 % 0.1 %
Organisms tested for Plasmodium spp, Leptospira spp, O tsutsugamushi, R
typhi, spotted-fever-group rickettsia, agents of
conventional bacteraemia, dengue fever, Japanese
encephalitis virus, influenza
Plasmodium spp, Leptospira spp, O tsutsugamushi,
R typhi, spotted-fever-group rickettsia, causes of
community bacteraemia, dengue fever, Japanese
encephalitis virus, influenza (in one of the two sites)
Plasmodium spp, Leptospira spp, O tsutsugamushi, R
typhi, spotted-fever-group rickettsia, causes of community












as controls to characterise procalcitonin and CRP levels
in a healthy population in the region.
Laboratory procedures
The VIDAS® B · R · A · H ·M · S PCT kit was used to de-
termine procalcitonin levels using the Enzyme-Linked
Fluorescent Assay technique via the Mini-VIDAS plat-
form (BioMérieux, 69280 Marcy-l'Etoile, France). The
assay has a lower level of detection of 0.05 ng/ml and a
measurement range of 0.05–195 ng/ml. CRP was
measured using a NycoCard Reader II (Axis Shield,
Kjelsåsveien 161, NO-0884 Oslo, Norway). The assay
has an effective range of 5–120 mg/L in serum and has
been validated for accuracy in both laboratory and rou-
tine care settings [25, 26]. All serum samples from the
original studies were stored at −85 °C before testing.
While steps were taken to prevent multiple freeze-thaw
cycles, we used five samples from the Cambodia study
to further confirm the stability of procalcitonin and CRP
levels over repeated freeze-thaw cycles. In approximately
20 % of cases there were insufficient volumes of serum
for the procalcitonin assay therefore these cases were ex-
cluded. All procalcitonin and CRP assay results were
read independently by two operators blinded to the
microbiological diagnosis, and double-entered to minim-
ise omissions or inaccuracies.
Statistical analysis
Procalcitonin and CRP values were summarised using
medians and ranges. These were compared across
aetiological groups using the Mann-Whitney U test for
two-group comparisons and the Kruskal-Wallis test for
multi-group comparisons. Non-parametric receiver op-
erating characteristic (ROC) curves were plotted and the
Wald test was used to compare areas under the curve.
Covariates included the following factors: patient admis-
sion (inpatients or outpatients), prior use of antibiotics,
and age group. The analyses were conducted for each of
the studies in isolation, and by merging data from all
studies and controlling for site effect in estimating the
area under the receiver operating curve (AUROC)
values.
To classify normal or elevated procalcitonin levels we
used established thresholds of 0.1 ng/mL, recommended
for lower acuity patients, as defined by the facility level
they attend and their admission status, and a more
widely used threshold of 0.5 ng/mL [21, 27]. For CRP we
used a threshold of 10 mg/L and 20 mg/L [17, 28]. Sen-
sitivity, specificity and likelihood ratios of procalcitonin
and CRP in detecting bacterial infections from a mixed
pool with viral infections were calculated with 95 % con-
fidence intervals using the Wilson Score method. The
analysis was performed using STATA 13 (College
Station, Texas).
Ethical approval
Ethical approval for the original studies was obtained from
the Angkor Hospital for Children Institutional Review
Board (IRB) in Cambodia, the Lao National Ethics
Committee for Health Research and the Mahidol
University Faculty of Tropical Medicine Ethics Committee
in Thailand, and from the Oxford Tropical Research
Ethics Committee (OXTREC). In all three sites patients or
their guardian signed an informed consent prior to inclu-
sion in the fever study; in the Laos and Thailand studies
this included use of the samples for future investigations
with similar aims. In Cambodia we obtained further ap-
proval from the hospital IRB as the original patient con-
sent form did not specify that other investigations with
similar aims could be performed. OXTREC was consulted
and no further ethical review was required.
Results
In total, 1372 patient samples were available for analysis.
Procalcitonin levels were significantly higher in the
Cambodian hospital, with a study population of paediat-
ric inpatients and mortality exceeding 5 %, than in the
other two community based sites where there was a
broader age distribution, a majority of outpatients and
mortality under 0.5 % (p < 0.001) (Fig. 1). For CRP there
were no significant differences between the sites. Among
the 100 controls, none had a raised procalcitonin level
and two had moderately raised CRP levels (10 and
31 mg/L).
Of the 1372 samples, 267 had multiple infections iden-
tified. Samples with a single diagnosis (n = 1105) were
classified into the four general aetiological groups: −
viral infections, rickettsia, and leptospira infections, bac-
teraemias, and malaria (Tables 2 and 3, Fig. 1). There
was no significant difference in gender ratio in each
group. In the Cambodian study, children under 5 years
were more likely to have a viral aetiology than older chil-
dren (68 % against 52 %, p < 0.001).
Procalcitonin and CRP levels were significantly
lower in patients with a viral infection than other in-
fections (p < 0.0001 in all comparisons apart from
procalcitonin values in the Cambodian site where this
was p = 0.01 for the difference between viral and
bacterial infections). The AUROC for CRP [0.83
(0.81–0.86)] in discriminating between all bacterial
and viral infections was significantly higher than that
for procalcitonin [0.74 (0.71–0.77)] (p < 0.0001). When
including only bacteraemias and viral infections CRP
had an AUROC of 0.89 (0.8–0.97) as compared with
0.78 for procalcitonin (0.65–0.90) in distinguishing
between the two aetiological groups (Fig. 2).
The samples included in this study were obtained from
a diverse group of patients. When controlling for covari-
ates (age group, admission status, previous use of
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antibiotics), the AUROC for CRP remained significantly
higher than that of procalcitonin. Being admitted as an
inpatient had an independent effect of elevated levels of
procalcitonin (p = 0.054) and CRP (p = 0.006). In a strati-
fied analysis by patient age group and by admission sta-
tus the AUROC for CRP remained statistically higher
than that for procalcitonin, as shown in Fig. 3.
The distribution of procalcitonin and CRP levels in
each of the aetiological groups with respect to the
threshold values are shown in Fig. 4. When compared
against their respective threshold values of 0.1 ng/mL
or 0.5 ng/mL (procalcitonin) and 10 mg/L or 20 mg/L
(CRP), elevated procalcitonin predicted the presence of
bacterial infection with a sensitivity of 90 % (87–92 %)
and a specificity of 39 % (35–43 %) using the lower
threshold of 0.1 ng/mL, or a sensitivity of 60 % (56–
65 %) and specificity of 76 % (72–79 %) for the higher
threshold of 0.5 ng/ml. For CRP at a threshold of
10 mg/L the sensitivity was 95 % (92–97 %) and the
specificity was 49 % (46–53 %); at a 20 mg/L threshold
the sensitivity was 86 % (82–88 %) and specificity was
67 % (63–71 %). The moderate positive likelihood ratio
of 1.9 for the lower CRP threshold therefore implies
limited additional benefit in confirming the presence of
Table 2 Samples excluded from the analysis due to insufficient volume and the samples included in the analysis by site
Cause of fever Excluded due to









Aetiological group (% of
samples with single infection)
Dengue 98 (25) 81 (19) 75 (14) 157 (37) 313 (23) Viral, n = 555 (50)
Japanese encephalitis 38 (10) 26 (6) 81 (16) 5 (1) 112 (8)
Influenza/RSV 23 (6) 32 (8) 98 (19) NA 130 (9)
Rickettsial infectiona 56 (15) 36 (8) 89 (17) 92 (21) 217 (16) Rickettsia/Leptospira, n = 334 (30)
Leptospirosis 39 (10) 7 (2) 70 (14) 40 (9) 117 (9)
Bacteraemia 46 (12) 59 (14) 20 (4) 11 (3) 91 (7) Bacteraemia, n = 91 (8)
Malaria 10 (3) 6 (1) 15 (3) 104 (24) 125 (9) Malaria, n = 125 (12)
Multiple pathogens 73 (19) 179 (42) 68 (13) 21 (5) 267 (19)
Total 383 426 (100) 516 (100) 433 (100) 1372 (100) 1105
These samples were a sub-set of the original study, to include only those with identified infections. The main focus of the analysis was on those samples with a
single pathogen that was identified as the cause of illness (allowing for co-infection with malaria PCR positive microscopy/RDT negative cases which are not
assumed to be the cause of fever)
aScrub or murine typhus
Fig. 1 Boxplots for the distribution of procalcitonin and CRP readings in the three sites, and data points for procalcitonin and CRP levels in viral
infections, rickettsia/leptospira, bacteraemia and malaria. Abbreviation: PCT, Procalcitonin; CRP, C reactive protein
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bacterial infections, but the negative likelihood ratio of
0.1 implies high confidence in ruling out the need for
antibiotics. The proportion of samples with elevated
procalcitonin and CRP levels by aetiology are shown in
Table 4.
Procalcitonin and CRP levels were significantly
higher in malaria infections as compared with viral
infections (p < 0.001). For CRP levels there was no
significant difference between bacterial infections and
malaria (p = 0.15) while procalcitonin levels were sig-
nificantly higher (p < 0.001). The AUROC value for
procalcitonin in discriminating between malaria and
bacterial infections was 0.69 (95 % CI 0.64–0.74) and
for CRP it was 0.54 (0.49–0.6).
In all sites, median procalcitonin and CRP levels for
samples with more than one identified pathogen were
higher than in those with a single pathogen, but these
differences were non-significant. In Cambodia, where
procalcitonin and CRP assays were carried out on sam-
ples without an identified pathogen there was no evi-
dence of a difference compared with samples with an
identified pathogen.
Discussion
This is the largest ever study to measure and compare
procalcitonin and C-reactive protein levels in malaria
endemic settings. While both biomarkers were elevated
in malaria and bacterial infections as compared with
viral infections, CRP was the more accurate biomarker
for predicting the presence of bacterial infections in
these samples. In addition, CRP holds pragmatic advan-
tages as it rises to higher concentrations in the presence
of infection, which may allow more accurate and low
cost point of care tests that rely on low volumes of
whole blood [29]. The commercial availability of CRP
rapid tests [30, 31] and their routine use in high-income
countries in community and hospital settings suggests
that the timeframe for possible adoption elsewhere
would be considerably shorter. Of these two well-













Acinetobacter bacteraemia 1 (2) 1 (1)
B. pseudomallei 6 (10) 6 (7)
E. coli 4 (7) 2 (10) 5 (46) 11 (12)
H. influenzae 4 (7) 4 (4)
K. pneumoniae 1 (2) 1 (1)
P. aeruginosa 1 (2) 1 (5) 2 (2)
S. aureus 18 (31) 18 (20)
S. pneumoniae 12 (20) 1 (9) 13 (15)
S. pyogenes 2 (3) 2 (2)
S. Typhi / S. Paratyphi 9 (15) 17 (85) 3 (27) 28 (32)
Salmonella spp. 1 (2) 1 (9) 2 (2)
Enterococcus sp. 1 (9) 2 (2)
Only samples for which sufficient volumes were available and without
evidence of co-infections were included in the analysis
Fig. 2 Receiver operating characteristic curves for procalcitonin and CRP in discriminating between aetiological groups. On the horizontal axis is
the sensitivity of the biomarkers and on the vertical axis is the false positive rate (1-specificity). Abbreviations: PCT, Procalcitonin; CRP, C reactive
protein; ROC, receiver operating characteristic curve
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established biomarkers we therefore consider CRP to be
more promising for further evaluation and development
for the context of primary care in the rural tropics.
Malaria is associated with elevated CRP [28, 32] and
the data from this study as well as the limited previous
evidence suggest this is also the case for procalcitonin
[14]. These biomarkers therefore have limited value in
guiding antibiotic treatment in parasitaemic individuals,
at least in the Southeast Asian setting. In an African
high transmission setting, a positive malaria RDT may
not be a reliable indication of malaria being the cause of
illness, particularly with histidine-protein D 2 antigen
based RDTs in severe cases [33, 34]; possible use of a
CRP test in malaria RDT positives in these settings war-
rants further investigation.
In low transmission settings most infections are symp-
tomatic and detected by malaria RDTs, but if a signifi-
cant proportion of the population is asymptomatically
infected with sub-patent infections and if this is associ-
ated with elevated CRP/ procalcitonin, this could com-
promise the utility of these biomarkers in guiding the
management of fevers in these settings. Further work is
currently being carried out to measure CRP levels in
asymptomatic, slide negative infections detected by
highly sensitive PCR.
In the literature comparing procalcitonin and CRP as
biomarkers of bacterial infection, procalcitonin was often
found superior, particularly in critical care [10, 35, 36].
This could be due to a faster reaction time in response to
infection, which could be advantageous in initiating treat-
ment as quickly as possible. Procalcitonin is also more
rapidly eliminated, which can be beneficial in guiding anti-
biotic termination in hospitalised patients. These advan-
tages however might be less apparent in the context of
community care in the rural tropics where access to treat-
ment is inherently slower and where health workers con-
tact with patients is less frequent. Of more relevance to
this context is the literature concerning primary care and
emergency department (ED) settings. These have shown
more variable results in terms of the comparative
ability of the two biomarkers to identify bacterial in-
fections [28, 37, 38]. One of the few available com-
parisons of PCT and CRP in non-malarial tropical
diseases was from the very different population of ill-
returned travellers, where CRP was also found to be
superior to procalcitonin in patients in discriminating
Fig. 3 AUROC for Procalcitonin and C-reactive protein levels by
admission status and age group
Fig. 4 Procalcitonin and C-reactive protein levels in the four aetiological groups by site. Abbreviation: AUROC—area under the receiver operating
curve; CRP—C-reactive protein
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between a confirmed viral infection (dengue) and
those with either typhoid or rickettsioses [39].
Ultimately the utility of these and other biomarkers
needs to be determined not in retrospective studies on
samples with imperfect diagnoses but in prospective
studies into their impact on clinical outcomes and anti-
biotic prescription. Meta-analyses of procalcitonin
guided treatment in respiratory infections (as opposed to
febrile patients in our study) found it to safely reduce
the use of antibiotics with no significant impact on mor-
tality, ICU admission or length of hospital stay [40, 41].
A recent Cochrane review of biomarkers to guide antibi-
otics in ARIs in primary care concluded that CRP was
the only sufficiently accurate biomarker for which point
of care tests are available that could safely and effectively
reduce the prescribing of antibiotics [17]. Most studies
concluded that the utility of these biomarkers was great-
est when interpreted in conjunction with clinical symp-
toms and other laboratory assessments. It is important
to emphasise that the context of patient care in the rural
tropics is very different—health workers often have min-
imal training or experience, and no access to other la-
boratory tests.
There are several limitations that need to be addressed
in further study. First, we included stored samples with a
single conservative diagnosis from a subset of patients
with undifferentiated fevers. Likewise, the performance
of the biomarkers could differ if other viral and bacterial
infections that were not investigated in the original stud-
ies were included in the groupings. The implications for
patients without a confirmed microbiological diagnosis
or with other pathogens are not clear. These findings
therefore are likely to be of high internal validity but their
generalizability needs to be better established in a pro-
spective cohort of consecutively recruited patients. Ultim-
ately establishing a microbiological cause of illness will
always be challenging, therefore in addition to comparing
biomarker levels in patients for whom a diagnosis is
available, what is most needed are studies exploring anti-
biotic prescription patterns and clinical outcomes when
guided by CRP or procalcitonin in these settings [42].
Second, there was variation between the studies in the
microbial pathogens investigated, laboratory procedures,
and algorithms used to determine a cause of illness. The
inclusion criteria also differed in terms of whether all fe-
brile patients were included or only those without a
clear focus of infection. However, the consistent per-
formance of CRP across the different studies indicates
that the findings are robust.
Third, the accuracy of the microbiological diagnoses
where available was likely to be imperfect. It is possible
that patients with an identified viral infection and ele-
vated procalcitonin or CRP might also be harbouring an
undetected pathogenic bacterial infection, as docu-
mented for example in hypotensive dengue patients with
translocation of gut bacteria [43]. While this detracts
from the apparent accuracy of the tests in misclassifying
bacterial infections as viral, in a routine setting the im-
plication would be that these cases are appropriately
treated with an antibiotic.
Fourth, there was considerable diversity in patient pro-
file including age and severity of illness between the
sites; the Cambodian site for instance included only
paediatric inpatients as compared with the Thai/
Myanmar study, which included primarily older outpa-
tients. Our main objective is to inform the management
of fever in community and primary care, therefore some
of these patient profiles might be more reflective of se-
vere cases attending higher level facilities. In practice
however, such distinctions might not hold in remote
areas where severely ill patients often present and re-
main at low level facilities.
Lastly, the thresholds used to define elevated procalci-
tonin and CRP levels might not be optimal; specifying
an optimal threshold requires further clinical and eco-
nomic evaluation.
Table 4 Percentage of patients with procalcitonin and C-reactive protein above threshold values
Aetiology PCT 0.1 ng/ml PCT 0.5 ng/ml CRP 10 mg/L CRP 20 mg/L
%, 95 % CI %, 95 % CI %, 95 % CI %, 95 % CI
Dengue 72 (67–77) 25 (21–31) 46 (40–52) 28 (23–33)
Japanese encephalitis 60 (50–69) 32 (24–41) 64 (55–73) 52 (43–62)
Influenza 34 (26–42) 16 (11–24) 49 (40–57) 29 (22–37)
Rickettsial infections 87 (82–91) 53 (47–60) 94 (90–97) 80 (75–85)
Leptospirosis 95 (91–98) 65 (57–72) 97 (92–99) 92 (87–96)
Bacteraemia 90 (82–95) 71 (60–80) 93 (85–97) 86 (77–92)
Malaria 96 (91–98) 79 (72–85) 93 (88–97) 87 (80–92)
In viral infections the proportion of patients with a raised procalcitonin level was consistently and significantly lower than that for CRP at 10 mg/L (p < 0.001). For
the higher CRP threshold of 20 mg/L the differences in specificity were not significant, except in the case of Japanese encephalitis
Abbreviation: PCT Procalcitonin; CRP C reactive protein
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Conclusions
Notwithstanding the need for further prospective studies
of CRP guided treatment in these settings, these findings
suggest that there may well be a role for CRP point of
care tests in guiding antibiotic treatment of fevers in
malaria endemic areas. A key advantage of this approach
is its simplicity. Malaria RDTs are already widely used
and therefore incorporation of a test with a similar for-
mat, preferably in a single device will not require exten-
sive further infrastructure or training. As compared with
using a range of aetiology specific tests, a single bio-
marker test is also likely to have lower costs and greater
robustness to temporal and spatial heterogeneity in fever
aetiology. Other biomarkers and technologies are under
development and some of these will undoubtedly even-
tually prove superior to a CRP immunoassay. Current
management of undifferentiated fever in the rural tro-
pics however is unacceptable, with dire health outcomes
from common treatable infections going undiagnosed,
while overconsumption of antibiotics contributes to a
potential global public health catastrophe. We believe
the addition of CRP rapid tests to current syndromic
based treatment algorithms could be a feasible, effective,
and affordable measure to improve healthcare delivery
across the tropics; further work to confirm this approach
is warranted.
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